Effectiveness, Safety, Adherence, and Health-related Quality of Life in HIV-1 Infected Adults Receiving Bictegravir/ Emtricitabine/Tenofovir Alafenamide
N/A
The primary objective of this study is to evaluate HIV-1 RNA suppression, d...
Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1
PHASE3
The goal of this clinical study is to learn about the safety and efficacy o...
Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants
PHASE3
The primary objective of this study is to evaluate the efficacy of switchin...
Efficacy and Safety of First-line ART With BIC/FTC/TAF Introduced at the First Clinical Visit
N/A
Bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) is a recommen...
Status
Completed
Location
University Hospital for Infectious Diseases ''Dr. Fran Mihaljevic''
Start Date
2019-05-01
Trial ID
NCT06518213
Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in Human Immunodeficiency Virus-1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults
PHASE3
The primary objective of this study is to evaluate the efficacy of a fixed ...